About Us
According to “Notice to institution recommending ‘technology boosts economy 2020’ crucial specialist project by the Technology Department”, Suzhou TongKang’s, a subsidiary of Wuhan Togo Meditech, “Commercialization of blood purification high-value supplies” project has been recommended by Jiangsu provincial department of technology as a “‘technology boosts economy 2020’ crucial specialist project”.
Under the circumstance of the global COVID-19 pandemic at the tail-end of 2019, our researcher worked under the direction of “COVID-19 treatment strategies (6th draft)” by the Chinese Department of Health, optimized our current blood purification technology in order to combat the pandemic. It`s currently being used for as a domestic replacement for blood purification high-value equipment, including Inflammatory factor adsorption column, Bilirubin Adsorption Column, providing key supplies for the treatment of COVID-19.
Our company engage in the research and development of Artificial extracorporeal liver support, along with its supplies, mainly used in treatment of liver failures. Our main product being Inflammatory factor adsorption column, Bilirubin Adsorption Column in the blood purification industry. We are a National High-tech company; in which the research and development of blood purification supply is carried out by our subsidiary Jiangsu TongKang.
This recommendation is highly valued by our company, not only will this help accelerate our process to commercialize Artificial extracorporeal liver support, it also supports the nation in the struggle against the pandemic.